Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical Limited has showcased promising findings at the Clinical Trials on Alzheimer’s Disease conference, revealing that the biomarker plasma pTau181 can predict the progression of mild Alzheimer’s. Their XanaMIA trial is currently utilizing this biomarker to refine patient selection, potentially enhancing the efficiency of Alzheimer’s research. The ongoing trial is evaluating the efficacy of Xanamem, a novel treatment targeting brain cortisol levels, with results anticipated in 2025.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
